The metabolism of acetyl tributyl citrate was evaluated using groups of male rats (number of animals, weights, and strain not stated). ... Both the absorption and metabolism of 14C-Acetyl tributyl Citrate proceeded rapidly, and the following metabolites were identified: acetyl citrate, monobutyl citrate, acetyl monobutyl citrate, dibutyl citrate, and acetyl dibutyl citrate.
IDENTIFICATION AND USE: Acetyl tributyl citrate (ATBC) is a colorless liquid. It is the most widely used phthalate substitute plasticizer. It is used in products such as food wrap, vinyl toys, and pharmaceutical excipients. It is also used as a flavor ingredient in non-alcoholic beverages. HUMAN EXPOSURE AND TOXICITY: The skin irritation potential of acetyl tributyl citrate was evaluated using 59 men and women, all of whom had history of diabetes, psoriasis, or active dermatoses. ATBC was nonirritating to the skin, and reactions suggestive of contact sensitization were not observed during the study. In vitro ATBC increased CYP3A4 messenger RNA (mRNA) levels and enzyme activity in the human intestinal cells but not in human liver cells. ANIMAL STUDIES: Acute oral toxicity of ATBC in cats and rats is low. CYP3A1 mRNA levels were increased in the intestine but not the liver of ATBC-treated rats. In a 90-day repeated-dose oral dietary study in rats, decreased body weight and organ weight changes were observed at 1000 mg/kg-bw/day. In a combined repeated dose/reproductive/developmental toxicity study in rats, organ weight and histopathological changes were observed in adults at 1000 mg/kg-bw/day. In a 2-generation reproductive toxicity study in rats, reduced body weight was observed in F1 males at 300 mg/kg-bw/day. In the same study, no other treatment related effects were observed. In the combined repeated dose/reproductive/developmental toxicity study in rats previously described, histopathological changes were observed in the liver of adult males at 300 mg/kg-bw/day. In the same study, decreased litter size and decreased number of implantations were observed at 1000 mg/kg-bw/day. ATBC did not induce gene mutations in bacteria or mammalian cells in vitro and did not induce chromosomal aberrations in mammalian cells in vitro. ECOTOXICITY STUDIES: For acetyl tributyl citrate, the 96-hr LC50 values for fish range from 38 to 60 mg/L, the 48-hr EC50 value for aquatic invertebrates is 7.8 mg/L and the 72-hr EC50 values for aquatic plants are 11.5 mg/L for biomass and 74.4mg/L for growth rate, respectively.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
对人类不具有致癌性（未被国际癌症研究机构IARC列名）。
No indication of carcinogenicity to humans (not listed by IARC).
来源:Toxin and Toxin Target Database (T3DB)
毒理性
副作用
神经毒素 - 其他中枢神经系统神经毒素
Neurotoxin - Other CNS neurotoxin
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
The metabolism of acetyl tributyl citrate was evaluated using groups of male rats (number of animals, weights, and strain not stated). Each animal received a single oral dose of 14C-acetyl tributyl citrate (dose not stated). At 48 hr post dosing, approximately 99% of the administered dose had been excreted either in urine (59% to 70%), feces (25% to 36%), or in the expired air (2%). Only 0.36% to 1.26% of the dose remained in the tissues or carcass.
邻苯二甲酸酯(2-) 、 Bis(2,4,5-trichlorophenyl-6-carbopentoxyphenyl)oxalate 、 乙酰柠檬酸三丁酯 、 双氧水 、 sodium salicylate 以and between about 85 wt. % and about 99 wt. % pure triethyl citrate formed的产率得到柠檬酸三乙酯
N-Heterocyclic carbene-catalyzed synthesis of acetyltributylcitrate via a transesterification reaction
摘要：
A new methodology for the synthesis of a green plasticizer acetyltributylcitrate through a transesterification reaction was developed. Under the catalysis of alkyl-substituted imidazol-type N-heterocyclic carbenes, tributyl citrate can react with vinyl acetate smoothly to give ATBC in high yield. (C) 2013 Lin He and Bin Dai. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
DOI：
10.1016/j.cclet.2013.11.034
作为试剂：
描述：
在
乙酰柠檬酸三丁酯 作用下，
220.0 ℃
、20.0 Pa
条件下，
以246 g的产率得到奥克立酯
[EN] QUINOLINE AND QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS QUINOLÉINE ET QUINAZOLINE
申请人：ACERTA PHARMA BV
公开号：WO2016055982A1
公开（公告）日：2016-04-14
In some embodiments, the invention relates to quinazoline and quinoline compounds of Formula I: (I) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to quinazoline and quinoline compounds, pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of Bruton's tyrosine kinase (BTK) mediated disorders.
[EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS<br/>[FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE
申请人：COLLABORATIVE MEDICINAL DEV LLC
公开号：WO2020185738A1
公开（公告）日：2020-09-17
The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.
[EN] NITRILE COMPOUND AND ITS USE IN PEST CONTROL<br/>[FR] COMPOSE NITRILE ET SON UTILISATION POUR LE CONTROLE DES INSECTES ET ANIMAUX NUISIBLES
申请人：SUMITOMO CHEMICAL CO
公开号：WO2005063694A1
公开（公告）日：2005-07-14
The present invention provides a nitrile compound represented by the formula (I): wherein R represents C1-C4 fluoroalkyl, Q represents halogen, C1-C11 alkyl optionally substituted with halogen, C2-C6 alkenyl group optionally substituted with halogen, C2-C6 alkynyl optionally substituted with halogen, C3-C7 cycloalkyl optionally substituted with halogen or (C3-C7 cycloalkyl optionally substituted with halogen)C1-C4 alkyl, which has excellent control effect against pests.
[EN] SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5<br/>[FR] INHIBITEURS SÉLECTIFS DE LA PROTÉINE ARGININE MÉTHYLTRANSFÉRASE 5
申请人：PRELUDE THERAPEUTICS INC
公开号：WO2020206299A1
公开（公告）日：2020-10-08
The disclosure is directed to methods of treatment using compounds of Formula (I).
披露的内容涉及使用式（I）化合物进行治疗的方法。
ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
申请人：Meng Charles Q.
公开号：US20140142114A1
公开（公告）日：2014-05-22
The present invention relates to novel anthelmintic compounds of formula (I) below:
wherein
Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X
1
, X
2
, X
3
, X
4
, X
5
, X
6
, X
7
and X
8
are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
